| Summary of Reconciles Reported Revenues to Net (Loss) Income under Significant Expense Principle |
The following table reconciles reported revenues to net loss under the significant expense principle for the three and nine months ended September 30, 2026 and 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended September 30, |
|
|
For the Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Collaboration revenue |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
20,000 |
|
|
$ |
— |
|
Research and development: |
|
|
|
|
|
|
|
|
|
|
|
|
RAP-219 program external expenses |
|
|
17,481 |
|
|
|
8,733 |
|
|
|
67,390 |
|
|
|
26,381 |
|
Preclinical programs external expenses |
|
|
4,473 |
|
|
|
4,474 |
|
|
|
13,632 |
|
|
|
12,442 |
|
R&D personnel-related costs (including stock-based compensation) |
|
|
10,559 |
|
|
|
7,381 |
|
|
|
31,836 |
|
|
|
20,833 |
|
Other costs |
|
|
1,803 |
|
|
|
1,691 |
|
|
|
5,588 |
|
|
|
4,875 |
|
Selling, general and administrative: |
|
|
|
|
|
|
|
|
|
|
|
|
G&A personnel-related costs (including stock-based compensation) |
|
|
7,486 |
|
|
|
5,487 |
|
|
|
21,554 |
|
|
|
15,491 |
|
Professional and consulting costs |
|
|
1,459 |
|
|
|
1,322 |
|
|
|
6,594 |
|
|
|
3,906 |
|
Facility related and other |
|
|
825 |
|
|
|
898 |
|
|
|
2,513 |
|
|
|
2,662 |
|
Loss from operations |
|
$ |
(44,086 |
) |
|
$ |
(29,986 |
) |
|
$ |
(129,107 |
) |
|
$ |
(86,590 |
) |
Interest income |
|
|
3,851 |
|
|
|
3,061 |
|
|
|
12,400 |
|
|
|
8,870 |
|
Net loss |
|
$ |
(40,235 |
) |
|
$ |
(26,925 |
) |
|
$ |
(116,707 |
) |
|
$ |
(77,720 |
) |
|